XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e. asks Dr. Suri.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

FEBRUARY 27, 2024

Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” More than 30 ATCs are already prepared to collect and ship tumor tissue from patients for Amtagvi manufacturing, said Iovance.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

Delveinsight

FEBRUARY 25, 2021

Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam adds to drug delivery stable with USD 120 Million GuideTx buy. GuideTx will aid Beam in developing LNP-based medicines.

DNA 52

DNA In-Vivo Genetics Medicine 52

pharmaphorum

NOVEMBER 16, 2022

This is the case for the new generation of treatments known as advanced therapies, which encompasses cell and gene therapies, as well as tissue engineering. However, with a price tag of €1.58 However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water. At more than $2.1

Gene Therapy 131

Gene Therapy Gene Marketing Development 131